Fig. 3.
Concentrations of lactosylcermide species and hexosylceramide species measured in 100 μl plasma samples obtained from type 1 diabetes patients with (n = 19) and without (n = 61) self-reported neuropathy using mass spectroscopy. Upper panel lactosylcermide species; lower panel hexosylceramide species. Data presented as mean + standard deviation